PLA2R1 and membranous glomerulonephritis: The ongoing investigator lead controlled trial REEBOOT (Belimumab with Rituximab for Primary Membranous Nephropathy) is enrolling patients across North America to evaluate its efficacy in combination with rituximab compared to rituximab alone in PLA2R positive patients (NCT03596385).